MET and ovarian cancer: As for miR‐613, its diminished expression seemed as a predictor for improved progression‐free survival and overall survival of ovarian cancer patients,50 and it also enhanced gastric cancer cells to progress by repression of brain‐derived neurotrophic factor.51 Our study displayed that c‐met was the downstream molecule of miR‐613, and they collaborated to modulate proliferation, viability, apoptosis and EMT process of retinoblastoma cells (Figures 6, 7, 8).